Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 29, 2016 07:30 ET | Source: Novavax, Inc.

Novavax Reports Fourth Quarter and Year-End 2015 Financial Results

GAITHERSBURG, Md., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
February 22, 2016 16:05 ET | Source: Novavax, Inc.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2015 Financial Results on February 29, 2016

GAITHERSBURG, Md., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
February 05, 2016 15:00 ET | Source: Novavax, Inc.

Novavax Announces Exercise of Over-Allotment Option to Purchase Additional Shares

GAITHERSBURG, Md., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
January 29, 2016 14:53 ET | Source: Novavax, Inc.

Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023

GAITHERSBURG, Md., Jan. 29, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
January 25, 2016 20:01 ET | Source: Novavax, Inc.

Novavax Prices $300 Million of Convertible Senior Notes Due 2023

GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
January 25, 2016 07:00 ET | Source: Novavax, Inc.

Novavax Announces Proposed Offering of $200 Million of Convertible Senior Notes Due 2023

GAITHERSBURG, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
January 08, 2016 08:30 ET | Source: Novavax, Inc.

Novavax Appoints Jeffrey Stoddard, M.D., Vice President, Medical Affairs

GAITHERSBURG, Md., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
January 06, 2016 16:02 ET | Source: Novavax, Inc.

Novavax to Present at the 34th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
December 21, 2015 16:05 ET | Source: Novavax, Inc.

Novavax Appoints Mark Twyman Vice President Marketing

GAITHERSBURG, Md., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...
December 14, 2015 16:05 ET | Source: Novavax, Inc.

Novavax Completes Enrollment of Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

GAITHERSBURG, Md., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant...